Skip to main content
. Author manuscript; available in PMC: 2010 Jun 21.
Published in final edited form as: Leuk Lymphoma. 2009 Dec;50(12):2017–2029. doi: 10.3109/10428190903147637

Figure 5. Inhibition of p38 Map Kinase reverses the pro-apoptotic effect of dasatinib in BAF3/p210 cells.

Figure 5

A. Logarithmically growing BAF3/p210 cells were treated with dasatinib (1nM) in the presence or absence of SB203580 (10µM) for 48 hrs. Cells were analyzed by flow cytometry for the degree of apoptosis by using AnnexinV/PI staining. Apoptosis index was calculated by dividing observed value by untreated value. (Dasatinib vs. dasatinib +SB203; 2-tailed p=0.01, n=6) B. Similar experiment to one shown in panel A except BAF3/P210 cells were incubated with dasatinib (1nM) in the presence or absence of p38siRNA (100nM) or controlsiRNA for 48 hrs as indicated. (Dasatinib vs. dasatinib +p38SiRNA; 2-tailed p=0.01, n=3) C. BAF3/p210 cells were incubated with dasatinib (1nM), for 48 hrs in presence or absence of SB203580 (10 µM). Equal amounts of total cell lysates (50µg/lane) were analyzed by SDS-PAGE and immunoblotted with antibody against the Cleaved Caspase-3 on Aspartate 175. The blot was then stripped and reprobed with an antibody against actin to control for protein loading.